STOCK TITAN

Codexis Inc - CDXS STOCK NEWS

Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.

Codexis Inc (CDXS) pioneers enzyme engineering solutions for biopharmaceutical manufacturing through its CodeEvolver and ECO Synthesis platforms. This page aggregates all official announcements and developments critical to understanding the company's trajectory.

Investors and industry professionals will find curated updates including earnings reports, strategic partnerships, product launches, and manufacturing innovations. Our collection ensures timely access to material information affecting therapeutic production efficiency.

Key content categories include financial performance disclosures, technology licensing agreements, enzyme optimization breakthroughs, and sustainability initiatives. All updates are sourced directly from verified corporate communications.

Bookmark this page for streamlined tracking of Codexis' advancements in protein engineering and RNA therapeutic manufacturing. Check regularly for developments impacting biotech production economics and pharmaceutical process optimization.

Rhea-AI Summary

Codexis (Nasdaq:CDXS) announces that President and CEO John Nicols will participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The recorded session will be accessible starting January 11 at 6:00 a.m. ET on the company's investor website, available for 30 days. Codexis specializes in protein engineering, utilizing its CodeEvolver® technology to enhance protein performance for pharmaceuticals, enzymes, and diagnostics, promoting sustainable manufacturing processes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
conferences
-
Rhea-AI Summary

Codexis (Nasdaq: CDXS) announced a public offering of 4,285,715 shares at $17.50 each, aiming to raise approximately $70.2 million after expenses. The offering is expected to close around December 7, 2020, pending customary conditions. Proceeds will support R&D and infrastructure to enhance performance enzymes and biotherapeutics, as well as fund potential acquisitions or investments. Jefferies LLC, Cowen and Company, LLC, and Stifel are managing the offering, with an additional 642,857 shares available for underwriters within 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.75%
Tags
-
Rhea-AI Summary

Codexis (Nasdaq: CDXS) has launched an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase an additional 15% of shares. The net proceeds will fund R&D, enhance infrastructure, and support the development of performance enzymes and biotherapeutics. Codexis may also invest in complementary businesses. Notably, Jefferies LLC, Cowen and Company, and Stifel are managing the offering. Market conditions may impact the completion and terms of this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.75%
Tags
Rhea-AI Summary

Codexis (NASDAQ: CDXS) and Casdin Capital have launched the SynBio Innovation Accelerator, aimed at funding early-stage companies in synthetic biology. This initiative will see Casdin planning to invest upwards of $50 million in the sector. The first investment is a $1.75 million stake in Arzeda, a computational protein design firm, where both companies will collaborate to enhance enzyme development using machine learning. John Nicols, CEO of Codexis, emphasized the transformative potential of synthetic biology, while Eli Casdin highlighted the accelerator's role in stimulating innovation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
none
-
Rhea-AI Summary

Codexis, a leader in protein engineering, announced its participation in three virtual investment conferences. The events include the Stifel Healthcare Conference on November 16, 2020, at 3:20 p.m. ET, the 11th Annual Craig-Hallum Alpha Select Conference on November 17, 2020, and the Stephens Annual Investment Conference on November 18, 2020, at 1:00 p.m. ET. Presentations will be webcasted and available for replay on the company's investor website. Codexis utilizes its proprietary technology for developing proteins for pharmaceuticals and industrial applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.97%
Tags
conferences
-
Rhea-AI Summary

Codexis, Inc. (Nasdaq: CDXS) reported total revenues of $18.4 million for Q3 2020, a drop from $21.9 million in Q3 2019. Product revenue was $8.4 million, down from $10.4 million year-over-year, largely due to demand timing. R&D revenue decreased to $10.0 million from $11.6 million, impacted by fewer milestone payments. Despite a net loss of $6.1 million, management expects 2020 revenue to exceed pre-COVID guidance, with robust growth across its segments, including Novel Biotherapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
Rhea-AI Summary

Codexis, a leader in protein engineering, is set to announce its third quarter 2020 financial results on November 5, 2020, after market close. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide company updates. Investors are encouraged to pre-register for the call to streamline access. The announcement underlines Codexis' focus on transparency and engagement with its investment community.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
none
-
Rhea-AI Summary

Codexis, a leading protein engineering company, announced its participation in two upcoming virtual investment conferences. The first event is the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 10:30 a.m. ET. The second is the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020, at 8:00 a.m. ET. A live webcast and replay will be available on their Investors website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
conferences
-
Rhea-AI Summary

Codexis, Inc. (NASDAQ: CDXS) will report its second quarter 2020 financial results on August 6, 2020, after the market closes. The management team will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company. Participants can pre-register for the call to receive a passcode for immediate access. A live webcast will also be available on the Codexis investor relations website, with an archive accessible for 90 days. For those unable to attend live, a replay will be available for 48 hours following the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
none
Rhea-AI Summary

Codexis (Nasdaq: CDXS) announces a partnership with Molecular Assemblies to enhance enzymatic DNA synthesis. Codexis will invest $1 million in Series A preferred stock and gain an expected ownership stake over 10% through performance milestones. This collaboration leverages Codexis' CodeEvolver® technology to improve DNA polymerase enzymes, facilitating cost-effective, high-quality DNA production across industries like pharmaceuticals and synthetic biology. Both companies aim to revolutionize DNA synthesis and enable innovations in biotherapeutics, diagnostics, and data storage solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
none
Codexis Inc

Nasdaq:CDXS

CDXS Rankings

CDXS Stock Data

175.62M
80.74M
2.44%
80.52%
3.66%
Biotechnology
Industrial Organic Chemicals
Link
United States
REDWOOD CITY